期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 127, 期 8, 页码 2881-2891出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI94549
关键词
-
资金
- NIH [R01 DK070011]
- JDRF [25-2013-268, 17-2011-594, 17-2012-3]
- Leona M. and Harry B. Helmsley Charitable Trust [2015PG-T1D052]
- Diabetes Research Institute Foundation, Hollywood, Florida
Type 1 diabetes (T1D) is a chronic autoimmune disease that causes severe loss of pancreatic beta cells. Autoreactive T cells are key mediators of beta cell destruction. Studies of organ donors with T1D that have examined T cells in pancreas, the diabetogenic insulitis lesion, and lymphoid tissues have revealed a broad repertoire of target antigens and T cell receptor (TCR) usage, with initial evidence of public TCR sequences that are shared by individuals with T1D. Neoepitopes derived from post-translational modifications of native antigens are emerging as novel targets that are more likely to evade self-tolerance. Further studies will determine whether T cell responses to neoepitopes are major disease drivers that could impact prediction, prevention, and therapy. This Review provides an overview of recent progress in our knowledge of autoreactive T cells that has emerged from experimental and clinical research as well as pathology investigations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据